CDK4 and neoplasm: Together, our results indicate that CDK4 gene expression is elevated in the aggressive basal-like TNBC subtype and correlates with TNBC poor clinical prognosis features (including ER and PR negative status and high tumor grade) and highlight CDK4 as a potential poor prognostic marker for TNBC patients.